Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Britain Courts Anthropic Amid US Defense Department Dispute 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
SAN DIEGO, Aug. 02, 2017 -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (the “Company”) will announce its second quarter 2017 financial results after market close on Monday, August 14, 2017.
TearLab’s Chief Executive Officer, Seph Jensen and Chief Financial Officer, Wes Brazell, will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
Second Quarter 2017 Results Conference Call Details:
Date: Monday, August 14, 2017
Time: 4:30 p.m. ET
Live Call: 877-303-1593 (Pass Code: 61973019)
Replay: 855-859-2056 (Pass Code: 61973019)
The call will also be broadcast live and archived on the Company's website at www.tearlab.com under the "Webcasts" tab in the Investor's section.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
Investor Contact: The Ruth Group Lee Roth Tel: 646-536-7012 [email protected]
